NTRA · NASDAQ
Natera, Inc.
$403.95 +2.26 (+0.56%)
Company overview
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorders; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage, and non-invasive paternity testing products to determine paternity using a blood draw from the pregnant mother and alleged father.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Exchange
- NASDAQ
- Market cap
- $58.2B
- Employees
- 4,424
- Headquarters
- Austin, CA
- Website
- natera.com
- CEO
- Steven Leonard Chapman
- Listed
- July 1, 2015
- P/E
- -247.82
- Dividend yield
- 0.00%
Company financials
- Revenue
- $2.5B
- Gross profit
- $1.6B
- Operating income
- -$324M
- EBITDA
- -$275M
- Net income
- -$226M
- EPS
- -$1.63
- Total assets
- $2.6B
- Total debt
- $240M
- Gross margin
- 65.16%
- Net margin
- -9.05%
- Earnings yield
- -0.40%
Showing FY 2025
NTRA
1D
NASDAQ
O408.47H416.00L383.76C401.37-12.01 (-2.91%)Vol1.61M